Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

BACKGROUND: Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong life in patients without HF. Ongoing event-driven trials are investigating whethe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Jesper, Omar, Massar, Kistorp, Caroline, Poulsen, Mikael Kjær, Tuxen, Christian, Gustafsson, Ida, Køber, Lars, Gustafsson, Finn, Fosbøl, Emil, Bruun, Niels Eske, Videbæk, Lars, Frederiksen, Peter Hartmund, Møller, Jacob Eifer, Schou, Morten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588901/
https://www.ncbi.nlm.nih.gov/pubmed/31227014
http://dx.doi.org/10.1186/s13063-019-3474-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588901/
https://www.ncbi.nlm.nih.gov/pubmed/31227014
http://dx.doi.org/10.1186/s13063-019-3474-5

Ejemplares similares